RENE.L

ReNeuron Group Plc
ReNeuron Group plc - Corporate Update
2nd August 2024, 11:25
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0291Z
ReNeuron Group plc
02 August 2024
 

2 August 2024

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Corporate Update

 

ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following corporate update in regards the Company's ongoing administration process ("Administration Process").

 

Update on Creditor Position

 

The Board of the Company took the decision to appoint Stephen Cork and Mark Smith of Cork Gully LLP as joint administrators to the Company (the "Joint Administrators") on 20 March 2024. Following their appointment, the Joint Administrators have been in discussion with ReNeuron's main creditors to the clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. To date, there is a discrepancy between the amount the Company is able to pay to its creditors in settlement of the total liability to them and the quantum that the creditors are seeking.

 

Update on Staff

 

As part of the Administration Process, and in order to preserve value for creditors, the Joint Administrators have undertaken a cost rationalisation which has included, inter alia, the redundancy of several of the Company's employees as well as other cost cutting measures. Certain members of key Senior Management, including the Board of Directors and Randolph Corteling (Chief Scientific Officer) have remained with the business and continue to support the Joint Administrators.

 

Update on Financing Discussions

 

The Company, with the assistance of its brokers, have been seeking to identify potential investors that would be willing to invest in new equity capital to enable the Company to continue to trade as a going concern following an exit from administration (the "Proposed Fundraise"). Whilst discussions remain ongoing with potential investors, it is anticipated that completion of the Proposed Fundraise would be conditional on the Company exiting administration retaining sufficient funds to settle all of its known creditors, such that any new funds raised from investors could be used by the Company for its working capital requirements going forward post administration.

 

There can be no guarantees as to the outcome of the ongoing discussions with creditors and potential investors. Further updates will be provided in due course.

 

Enquiries:

 

Cork Gully LLP

+44 (0)20 7268 2150 or

Stephen Cork, Joint Administrator

reneuron@corkgully.com

Mark Smith, Joint Administrator


 


ReNeuron

www.reneuron.com/investors

Iain Ross, Executive Chairman

Via Walbrook PR





Allenby Capital Limited (Nominated Adviser and Broker)

+44 (0)20 3328 5656

James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)


Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)




 




 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFFLTFIFIIS]]>
TwitterFacebookLinkedIn